ENTITY
Junshi Biosciences

Junshi Biosciences (1877 HK)

309
Analysis
Health Care • China
Junshi Biosciences is an innovation-driven biopharmaceutical company focused on the discovery, development, clinical research, and commercialization of innovative therapeutics. Its key products, including toripalimab injection, Etesevimab, and adalimumab injection, are used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The company was founded in December 2012 and is headquartered in Shanghai, China.
more
bearish•HJ Science
•08 Jun 2026 10:00

HJ Science (华健未来) Pre-IPO: Thoughts on Valuation

HJ Science is seeking to raise at least USD100m via a Hong Kong listing. We value the four pipeline assets at USD317m on a China SOTP basis.

Logo
157 Views
Share
•07 Jun 2026 10:00

A-H Premium Weekly (Jun 5th): Yankuang Energy, Haier Smarthome, Times Electric, China Coal, Ping An

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Yankuang Energy, Haier Smarthome, Times Electric, China...

Logo
138 Views
Share
•03 May 2026 10:05

HK Connect Flows Weekly (Apr 30th): Alibaba, China Mobile, CNOOC, Tencent, Xiaomi, CCB, Cig Shanghai

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, China Mobile, CNOOC, Tencent, Xiaomi, CCB, Cig...

Logo
425 Views
Share
•26 Apr 2026 10:05

HK Connect Flows Weekly (Apr 24th): China Mobile, CCB, ICBC, CNOOC, Pop Mart Intl, Tencent

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for China Mobile, CCB, ICBC, CNOOC, Pop Mart Intl, Tencent.

Logo
334 Views
Share
•21 Apr 2026 06:15

Mabwell (Shanghai) Bioscience IPO: Aiming for Next Level of Growth Riding on ADC Pipeline

Mabwell seeks to raise ~$185M via HK IPO, which consists of 47M H shares. Offer price range is HK$27.64–30.71 per share. Subscriptions will close...

Logo
247 Views
Share
x